Roche gets FDA approval for HER2 breast cancer diagnostic
pharmaphorum
OCTOBER 4, 2022
Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer patients. HER2 is a receptor protein that accelerates cancer cell growth.
Let's personalize your content